Speciality: Hematology
Description:
A warm welcome to all the medical professionals in this memorable scientific session of thromboprophylaxis in medical settings. We have Dr. Ashish Bhalla, Dr. Tobias Tritschler and Dr. Bharat Jagiasi to lead this session.
The primary subject of discussion in this webinar is the increasing risk of hospital acquired deep vein thrombosis and pulmonary embolism among the patients. Get a broader knowledge of the above mentioned topics by learning about different instances.
Venous thromboembolism is the most common cause of death observed in surgical patients. Thromboprophylaxis is the mechanical method to promote venous outflow from the legs and antithrombotic drugs. This can be an effective means of reducing morbidity and mortality in the patients with hospital acquired deep vein thrombosis.
Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
MRD-Guided Azacitidine May Delay Relapse in AML, MDS
2.
According to JAMA, women who have false-positive mammogram results are at a higher risk of developing breast cancer over time.
3.
COVID-19 mRNA vaccines could unlock the next revolution in cancer treatment
4.
It has been discovered that personalized dosing in the treatment of prostate cancer improves patient outcomes.
5.
Both men and women who receive the HPV vaccine have a lower risk of developing multiple cancer types.
1.
Cracking Oncology Drug Resistance: New Strategies to Overcome Challenges in Modern Cancer Therapy
2.
Case Study: Genomic Medicine in Precision Oncology
3.
Understanding Mean Corpuscular Volume: A Comprehensive Guide
4.
Cardio-Oncology: Managing Heart Failure in Survivors of Cancer
5.
Advancing Medical Oncology: Education, Certification, Clinical Trials, and Evolving Treatment Pathways
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
2.
Navigating the Complexities of Ph Negative ALL - Part XVI
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation